Searched for
CIPLA WEIGHT MANAGEMENT
These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsIn just a few days, the Q1 earnings season for FY27 will start. But before that will come the season of business updates. And that needs to...- For low risk-takers: 5 large-caps from different sectors with an upside potential of up to 31%Now, there is nothing wrong with being bullish, because it has always paid to be bullish. Yes, one might argue that it has not paid in the ...
- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...
- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- Nifty in control of FIIs? The unlucky 13 bluechips facing the hardest institutional selloffForeign investors have significantly reduced holdings in many Nifty companies since September 2024. This has impacted top blue-chip stocks,...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Most hated stocks: FIIs dumping these 146 companies without a break for 4 straight quarters. Do you own any?Foreign institutional investors have been consistently selling shares in 146 Indian companies for four consecutive quarters. This selling s...
- Alkem Labs CEO Vikas Gupta may exit companyAlkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Cipla plans deeper push in domestic market and chronic therapies over next 2–3 yearsCipla's incoming MD and CEO-designate, Achin Gupta, outlined a two-to-three-year strategy focusing on deepening the domestic market presenc...
- Cipla launches drug for obesity, diabetesCipla has launched Yurpeak, a new injectable medication for obesity and type-2 diabetes. This one-weekly therapy, tirzepatide, is now avail...
- Novo Nordisk ties up with Emcure to expand reach of weight-loss drug semaglutide in IndiaNovo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand n...
- Cipla to sell Lilly's weight-loss drug in IndiaEli Lilly and Cipla have joined forces. Cipla will now market Lilly's popular weight-loss drug in India. The medication will be sold under ...
- Lilly, Cipla ink distribution pact for weight loss, type 2 diabetes treatment drug YurpeakIn an exciting collaboration, Cipla and Eli Lilly have unveiled Yurpeak, a groundbreaking diabetes and weight management medication, now av...
- Cipla eyes entry into India's weight management market amid rising demand and global competitionCipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also strengthening it...
- Sun Pharma aims to launch anti-obesity and type 2 diabetes drug Utreglutide in five years: Dilip ShanghviSun Pharmaceutical, India's largest drugmaker by revenue, plans to launch its experimental anti-obesity and type 2 diabetes drug Utreglutid...
- Cipla, DNDi launch 4-in-1 antiretroviral treatment for children with HIVSouth African Health Products Regulatory Authority (SAHPRA) has approved the sweet-tasting, heat-stable and '4-in-1' fixed-dose combination...
- Back on the growth wagon: Cipla is a favourite of analysts and this week's stock pickCipla reported an FCF of around Rs 3,400 crore in 2019-20 and is expected to report bigger numbers in the coming years due to increased gro...
- Analysts bet on Cipla as acquisitions expected to boost company's growthAcquisitions of two companies in the US will help Cipla increase its foothold in the market and has made analysts bullish on the counter.
- Brokerages downgrade Cipla on slower growth prospects; stock slipsMorgan Stanley and CLSA downgraded their ratings on Cipla after the drug maker reported a slower-than-expected rise in October-December net...
Load More
